Research programme: cancer therapeutics - Modern Biosciences
Latest Information Update: 23 Aug 2007
At a glance
- Originator University of Manchester; University of Salford
- Developer Modern Biosciences
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 23 Aug 2007 Preclinical development is ongoing